Gilbert Lefèvre is Senior Expert in pharmaceutical development with twenty-five year experience in both the early and late development arena. Dr. Lefèvre received his Ph.D. degree in biology and life sciences in 1989 from the University of Paris, Jussieu Campus, Paris, France, and was trained in general immunology at Pasteur Institute, Paris, France. After his Ph.D. degree, Dr. Lefèvre was instrumental in building a biotech startup to manufacture antibodies and immunological tests for the diagnosis of infectious diseases for hospital use. Dr. Lefèvre then joined the pharmaceutical company Ciba-Geigy in 1991 in Paris as Head of Immunobioanalytics and Pharmacokinetics, and, in 1997, he moved to Novartis headquarters in Basle, Switzerland. Dr. Lefèvre has a solid scientific expertise in pharmacokinetics, pharmacodynamics, dose/exposure-response relationships, and clinical pharmacology. With nine successful NDAs, Dr. Lefèvre also has a solid regulatory experience including completion of nonclinical and clinical pharmacology and biopharmaceutics components for regulatory submissions and defense and negotiation with health authorities worldwide. Dr. Lefèvre is leading international teams dedicated to projects in neurosciences, tropical medicines, and infectious diseases. Dr. Lefèvre reviews health authority guidance (including WHO) and is at the editorial board of several international journals and member of peer-review panels. Dr. Lefèvre was awarded the Prix Galien US in 2010 for the antimalarial compound Coartem/Riamet.
Biography Updated on 12 April 2016